Dr. Suzuki has recently identified hematopoietic stem cells with high-dose HMGCoA reductase inhibitors (statins) and intracoronary injection of autologous mesenchymal stem cells (MSCs) increased cardiogenic stem cells in the myocardium. The quantity of myocytes reentering the growth phase of the cell cycle is proportional to the amount of primitive (CD 133 positive) hematopoietic stem cells which are mobilized in the heart. The Suzuki lab will test the hypothesis that synergism occurs with these two therapeutic approaches and can improve flow and myocardial function in swine with ischemic cardiomyopathy. The results of this translational research project will provide the experimental basis for the design of subsequent clinical trials to examine whether mesenchymal stem cells with statin background can ameliorate heart failure and improve myocardial perfusion in patients with ischemic cardiomyopathy.
Suzuki, G., Iyer, V., Lee, T.C. and Canty, J.M. Jr. (2007). Intracoronary injection of autologous mesenchymal stem cells (MSCs) increases the myocardial localization of CD133+ hematopoietic stem cells (HSCs) in swine with hybernating myocardium. Circulation (Suppl II): 11-133, 2007. (Abstract)
Suzuki, G., Lee, T.C., Canty, J.M., Jr. (2006). Intracoronary fibroblast growth factor (AdvFGF-5) increases the myocardial localization of CD133+ hematopoietic stem cells (HSCs) in swine with hibernating myocardium. Circulation. 114 (Suppl II):II-125-II-126, 2006. (Abstract)